Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Hu, Zheng, Pan, Xiao-Fen, Wu, Fu-Qun, Ma, Li-Yuan, Liu, Da-Peng, Liu, Ying, Feng, Ting-Ting, Meng, Fan-Yi, Liu, Xiao-Li, Jiang, Qian-Li, Chen, Xiao-Qin, Liu, Jing-Lei, Liu, Ping, Chen, Zhu, Chen, Sai-Juan, Zhou, Guang-Biao
格式: Artigo
語言:Inglês
出版: Public Library of Science 2009
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://ncbi.nlm.nih.gov/pubmed/19606213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006257
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍